EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE ‐ STOP219 study

Noriyoshi Iriyama iD, Naoto Takahashi iD, Katsumichi Fujimaki, Takaaki Ono, Masuho Saburi iD, Masahide Yamamoto, Fumihiko Kimura, Eisei Kondo iD, Nobuyuki Aotsuka, Hiroki Yokoyama, Seiichiro Katagiri, Yosuke Minami und 11 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70678 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Noriyoshi Iriyama und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Imidazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment‐free remission (TFR) is now a key goal for chronic‐phase chronic myeloid leukaemia (CML‐CP) after achievement of a prolonged deep molecular response. About half of these patients can remain in remission without treatment, whereas those who relapse must resume lifelong therapy. This study investigated whether patients who previously failed tyrosine kinase inhibitor discontinuation could achieve TFR after receiving ponatinib as maintenance therapy. Patients who had relapsed after prior tyrosine kinase inhibitor (TKI) discontinuation and subsequently regained molecular response 4.5 (MR4.5; defined as a BCR‐ABL1 transcript level ≤0.0032% on the International Scale [IS]) were enrolled, switched to ponatinib (15 mg/day) for 12 months and those who maintained MR4.5 discontinued TKI therapy. The primary end‐point was the proportion of patients with TFR at 12 months. Patients losing major molecular response (MMR) resumed ponatinib or their prior TKI. Of 50 enrolled patients, 49 received ponatinib and 41 proceeded to TKI discontinuation. At 12 months, the proportion of patients with TFR was 36.6% (90% confidence interval: 24.1–50.6). Univariate analysis identified favourable factors for TFR: first discontinuation of imatinib, longer initial TKI therapy and longer first TFR duration. In conclusion, ponatinib maintenance followed by a second attempt at TKI discontinuation may facilitate successful TFR in selected CML patients. However, the risk of adverse events highlights the need for careful patient selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLeukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsPyridazinesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedFusion Proteins, bcr-ablJapanMaintenance ChemotherapyRemission InductionTreatment Interruption

Stichwörter der Autor:innen

chronic myeloid leukaemiaponatinibsecond discontinuation attempttreatment‐free remissiontyrosine kinase inhibitor

Substanzen

Fusion Proteins, bcr-ablImidazolesponatinibProtein Kinase InhibitorsPyridazines

Autor:innen und Institutionen

  • Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
  • Department of Hematology and Rheumatology, NHO Saitama Hospital, Saitama, Japan.
  • Department of Hematology, Nephrology, and Rheumatology, Akita University School of Medicine, Akita, Japan.
  • Department of Hematology, Fujisawa City Hospital, Fujisawa, Kanagawa, Japan.
  • Division of Transfusion and Cell Therapy, Hamamatsu University Hospital, Shizuoka, Japan.
  • Department of Hematology, Oita Prefectural Hospital, Oita, Japan.

ORCID-Profile: Noriyoshi Iriyama, Naoto Takahashi, Masuho Saburi, Eisei Kondo, Maho Ishikawa

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Iriyama, N., Takahashi, N., Fujimaki, K., Ono, T., Saburi, M., Yamamoto, M., Kimura, F., Kondo, E., Aotsuka, N., Yokoyama, H., Katagiri, S., Minami, Y., Ishikawa, M., Kuwatsuka, Y., Miura, M., Saito, A. M., Saito, T. I., Matsumura, I., Miyazaki, Y., …, & Kiyoi, H. (2026). Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE ‐ STOP219 study. British Journal of Haematology. https://doi.org/10.1111/bjh.70678

Vancouver

Iriyama N, Takahashi N, Fujimaki K, Ono T, Saburi M, Yamamoto M, et al. Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE ‐ STOP219 study. British Journal of Haematology. 2026. doi:10.1111/bjh.70678

BibTeX
@article{Iriyama2026,
  author = {Iriyama, Noriyoshi and Takahashi, Naoto and Fujimaki, Katsumichi and Ono, Takaaki and Saburi, Masuho and Yamamoto, Masahide and Kimura, Fumihiko and Kondo, Eisei and Aotsuka, Nobuyuki and Yokoyama, Hiroki and Katagiri, Seiichiro and Minami, Yosuke and Ishikawa, Maho and Kuwatsuka, Yachiyo and Miura, Masatomo and Saito, Akiko M and Saito, Toshiki I and Matsumura, Itaru and Miyazaki, Yasushi and Sakaida, Emiko and Maeda, Yoshinobu and Yamauchi, Takahiro and Kiyoi, Hitoshi},
  title = {Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE ‐ STOP219 study},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70678}
}
Kostenlos starten →